Equities Analysts Issue Forecasts for ABEO FY2024 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO) – Stock analysts at HC Wainwright upped their FY2024 earnings per share estimates for shares of Abeona Therapeutics in a research report issued to clients and investors on Monday, November 25th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($1.16) per share for the year, up from their prior estimate of ($1.26). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.17) EPS.

A number of other research analysts also recently commented on ABEO. Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th.

Abeona Therapeutics Stock Up 1.5 %

NASDAQ ABEO opened at $6.03 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The company has a market capitalization of $262.13 million, a P/E ratio of -2.24 and a beta of 1.52. Abeona Therapeutics has a one year low of $3.05 and a one year high of $9.01. The stock has a 50 day moving average price of $6.21 and a 200-day moving average price of $5.30.

Institutional Trading of Abeona Therapeutics

Institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC purchased a new stake in Abeona Therapeutics in the first quarter worth $91,000. Rosalind Advisors Inc. purchased a new stake in Abeona Therapeutics in the second quarter worth $7,420,000. Bank of New York Mellon Corp increased its stake in Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after purchasing an additional 2,434 shares during the period. Renaissance Technologies LLC increased its stake in Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after purchasing an additional 429,456 shares during the period. Finally, Simplify Asset Management Inc. purchased a new stake in Abeona Therapeutics in the second quarter worth $1,732,000. 80.56% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.